Immix Biopharma (IMMX) Expected to Announce Earnings on Monday

Immix Biopharma (NASDAQ:IMMX) is projected to issue its Q4 2025 results before the market opens on Monday, March 23rd. Analysts expect the company to announce earnings of ($0.16) per share for the quarter. Investors may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Wednesday, March 25, 2026 at 4:00 PM ET.

Immix Biopharma Stock Down 5.9%

NASDAQ:IMMX opened at $9.11 on Friday. Immix Biopharma has a 52 week low of $1.34 and a 52 week high of $11.61. The company has a fifty day simple moving average of $7.37 and a two-hundred day simple moving average of $5.04. The company has a market cap of $482.47 million, a price-to-earnings ratio of -11.83 and a beta of 0.25.

Hedge Funds Weigh In On Immix Biopharma

Large investors have recently bought and sold shares of the business. Balyasny Asset Management L.P. acquired a new position in shares of Immix Biopharma during the 4th quarter worth about $67,000. Velan Capital Investment Management LP lifted its stake in Immix Biopharma by 40.0% during the third quarter. Velan Capital Investment Management LP now owns 35,000 shares of the company’s stock worth $73,000 after purchasing an additional 10,000 shares during the last quarter. Tocqueville Asset Management L.P. lifted its stake in Immix Biopharma by 37.4% during the third quarter. Tocqueville Asset Management L.P. now owns 40,250 shares of the company’s stock worth $84,000 after purchasing an additional 10,950 shares during the last quarter. Squarepoint Ops LLC acquired a new position in Immix Biopharma in the fourth quarter valued at approximately $112,000. Finally, Quadrature Capital Ltd acquired a new position in Immix Biopharma in the fourth quarter valued at approximately $116,000. Hedge funds and other institutional investors own 11.26% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on IMMX shares. Wall Street Zen downgraded Immix Biopharma from a “hold” rating to a “sell” rating in a report on Sunday, March 15th. Citizens Jmp started coverage on Immix Biopharma in a research note on Monday, March 9th. They issued an “outperform” rating and a $23.00 price objective for the company. Mizuho assumed coverage on shares of Immix Biopharma in a research note on Monday, February 9th. They set an “outperform” rating and a $14.00 target price on the stock. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immix Biopharma in a report on Thursday, January 22nd. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $15.00.

Immix Biopharma Company Profile

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.